Literature DB >> 2375648

Late recurrence of malignant melanoma. Analysis of 168 patients.

N J Crowley1, H F Seigler.   

Abstract

Analysis of 7104 patients with melanoma seen at Duke University identified 168 who experienced their first recurrence 10 or more years after diagnosis, for an incidence of 2.4%. This included patients with all stages of disease. There was no sex, age, or primary site predominance. The mean disease-free interval for cutaneous melanomas was 14.3 years versus 22.3 years for ocular primary melanomas. The prognosis following relapse was related to the site of recurrence. Survival after local or regional node recurrence was often prolonged; survival after distant metastases was usually limited. Patients with ocular primaries had the highest incidence of distant metastases, and the shortest subsequent survival. An additional 483 patients were identified who survived 10 or more years without evidence of recurrence; of these 651 patients with long disease-free intervals, 25% (168 of 651) developed recurrent disease. This demonstrates that a 10-year disease-free interval cannot be considered a cure, and emphasizes the importance of continued annual follow-up.

Entities:  

Mesh:

Year:  1990        PMID: 2375648      PMCID: PMC1358053          DOI: 10.1097/00000658-199008000-00010

Source DB:  PubMed          Journal:  Ann Surg        ISSN: 0003-4932            Impact factor:   12.969


  9 in total

1.  The incidence of late recurrence (greater than 10 years); an analysis of 536 consecutive cases of cutaneous melanoma.

Authors:  M P Callaway; J C Briggs
Journal:  Br J Plast Surg       Date:  1989-01

2.  Recurrent malignant melanoma following a 46-year disease-free interval.

Authors:  L Rosenkranz; C Schroeder
Journal:  N Y State J Med       Date:  1985-03

3.  Late recurrence (beyond ten years) of cutaneous malignant melanoma. Report of two cases and a review of the literature.

Authors:  H K Koh; A J Sober; T B Fitzpatrick
Journal:  JAMA       Date:  1984-04-13       Impact factor: 56.272

4.  Predictors of late deaths among patients with clinical stage I melanoma who have not had bony or visceral metastases within the first 5 years after diagnosis.

Authors:  C L Day; M C Mihm; A J Sober; M N Harris; A W Kopf; T B Fitzpatrick; R A Lew; T J Harrist; F M Golomb; A Postel; P Hennessey; S L Gumport; J W Raker; R A Malt; A B Cosimi; W C Wood; D F Roses; F Gorstein; D Rigel; R J Friedman; M M Mintzis
Journal:  J Am Acad Dermatol       Date:  1983-06       Impact factor: 11.527

5.  Late relapse from cutaneous stage I malignant melanoma.

Authors:  H M Shaw; C W Beattie; W H McCarthy; G W Milton
Journal:  Arch Surg       Date:  1985-10

6.  Late recurrence of malignant melanoma.

Authors:  W B Sweeney; L P James; B C Ghosh; Z Vesoulis
Journal:  Am Fam Physician       Date:  1988-04       Impact factor: 3.292

7.  Late metastases (beyond ten years) of cutaneous malignant melanoma. Literature review and case report.

Authors:  D Raderman; S Giler; A Rothem; M Ben-Bassat
Journal:  J Am Acad Dermatol       Date:  1986-08       Impact factor: 11.527

8.  Survival in metastatic ocular melanoma.

Authors:  S Rajpal; R Moore; C P Karakousis
Journal:  Cancer       Date:  1983-07-15       Impact factor: 6.860

9.  Late recurrence of cutaneous melanoma.

Authors:  H A Briele; C W Beattie; S G Ronan; P K Chaudhuri; T K Das Gupta
Journal:  Arch Surg       Date:  1983-07
  9 in total
  42 in total

1.  [Symptomatic impairment of urine transport after malignant melanoma of the choroid].

Authors:  T Heinke; R Bonfig; E W Gerharz; H Griesser; H Riedmiller
Journal:  Ophthalmologe       Date:  2005-07       Impact factor: 1.059

2.  Late recurrence of malignant melanoma presenting as small bowel intussusception.

Authors:  Bernardino Rampone; Franco Roviello; Daniele Marrelli; Giovanni De Marco; Simone Rossi; Giovanni Corso; Guido Cerullo; Enrico Pinto
Journal:  Dig Dis Sci       Date:  2006-06       Impact factor: 3.199

Review 3.  Dormancy of metastatic melanoma.

Authors:  Liliana Ossowski; Julio A Aguirre-Ghiso
Journal:  Pigment Cell Melanoma Res       Date:  2009-10-19       Impact factor: 4.693

4.  Complete resection of isolated hepatic metastatic uveal melanoma with a notably long disease-free period: A case report and review of the literature.

Authors:  Shengzhang Lin; Dalong Wan; Haiyong Chen; Kangjie Chen; Shusen Zheng
Journal:  Oncol Lett       Date:  2015-05-18       Impact factor: 2.967

5.  Risk factors for residual and recurrent and metastatic uveal melanoma after trans-scleral local resection.

Authors:  W A Manschot
Journal:  Br J Ophthalmol       Date:  1996-11       Impact factor: 4.638

6.  Intravitreous Cutaneous Metastatic Melanoma in the Era of Checkpoint Inhibition: Unmasking and Masquerading.

Authors:  Jasmine H Francis; Duncan Berry; David H Abramson; Christopher A Barker; Chris Bergstrom; Hakan Demirci; Michael Engelbert; Hans Grossniklaus; Baker Hubbard; Codrin E Iacob; Korey Jaben; Madhavi Kurli; Michael A Postow; Jedd D Wolchok; Ivana K Kim; Jill R Wells
Journal:  Ophthalmology       Date:  2019-09-24       Impact factor: 12.079

Review 7.  Follow-up in patients with low-risk cutaneous melanoma: is it worth it?

Authors:  Ulrike Leiter; Thomas Eigentler; Claus Garbe
Journal:  Melanoma Manag       Date:  2014-12-04

8.  A nine-gene signature predicting clinical outcome in cutaneous melanoma.

Authors:  G Brunner; M Reitz; A Heinecke; A Lippold; C Berking; L Suter; J Atzpodien
Journal:  J Cancer Res Clin Oncol       Date:  2012-10-09       Impact factor: 4.553

Review 9.  Long-term follow-up for melanoma patients: is there any evidence of a benefit?

Authors:  Natasha M Rueth; Kate D Cromwell; Janice N Cormier
Journal:  Surg Oncol Clin N Am       Date:  2015-01-24       Impact factor: 3.495

10.  Late pulmonary metastases from malignant melanoma of the left planta.

Authors:  Hiroaki Toba; Kazuya Kondo; Koichiro Kenzaki; Takanori Miyoshi; Shoji Sakiyama; Akira Tangoku
Journal:  Gen Thorac Cardiovasc Surg       Date:  2009-10-16
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.